Preclinical Development
Lead Optimisation
Lead Generation
Early Discovery
Therapeutic area Neuropathic Pain
Background info
Intellectual property

Project Aim

To develop an agonist of Galanin Receptor 2 (GalR2) for the treatment of pain


Potential to address current unmet need in chronic pain with an improved side-effect profile to current therapies

Target Class

G-Protein Coupled Receptor (GPCR)


Biotherapeutic agent

Current Status

Discovery with in-vivo proof of efficacy

Intellectual Property

Opportunity to create a protective IPR portfolio


Licence or collaboration for pre-clinical / clinical development

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities